Show simple item record

dc.contributor.authorCummings, Jeffrey
dc.contributor.authorWard, Timothy H
dc.contributor.authorRanson, Malcolm R
dc.contributor.authorDive, Caroline
dc.date.accessioned2009-08-21T10:31:01Z
dc.date.available2009-08-21T10:31:01Z
dc.date.issued2004-12-10
dc.identifier.citationApoptosis pathway-targeted drugs-from the bench to the clinic. 2004, 1705 (1):53-66 Biochim. Biophys. Actaen
dc.identifier.issn0006-3002
dc.identifier.pmid15585173
dc.identifier.doi10.1016/j.bbcan.2004.09.005
dc.identifier.urihttp://hdl.handle.net/10541/78136
dc.description.abstractIt is an exciting time for cancer researchers in the field of apoptotic cell death. The avalanche of discoveries over the past decade or so regarding how apoptosis is regulated begins to be exploited for therapeutic benefit as the first apoptosis-targeted drugs enter early clinical trials. This chapter provides a selective review on the development of such drugs. We also outline issues regarding the regulation and design of early clinical trials of this type of molecularly targeted agent. Finally, we discuss the biomarkers and surrogate pharmacodynamic endpoint assays currently available to chart the efficacy of apoptosis-inducing anticancer therapy.
dc.language.isoenen
dc.subjectCanceren
dc.subjectBiological Tumour Markersen
dc.subject.meshApoptosis
dc.subject.meshCell Survival
dc.subject.meshClinical Trials as Topic
dc.subject.meshDrug Design
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.subject.meshPhosphotransferases
dc.subject.meshProto-Oncogene Proteins c-bcl-2
dc.subject.meshQuality Control
dc.subject.meshSignal Transduction
dc.subject.meshTumor Markers, Biological
dc.titleApoptosis pathway-targeted drugs-from the bench to the clinic.en
dc.typeArticleen
dc.contributor.departmentClinical and Experimental Pharmacology Group, Cancer Research UK Paterson Institute, Wilmslow Road, Manchester M20 4BX, UK.en
dc.identifier.journalBiochimica et Biophysica Actaen
html.description.abstractIt is an exciting time for cancer researchers in the field of apoptotic cell death. The avalanche of discoveries over the past decade or so regarding how apoptosis is regulated begins to be exploited for therapeutic benefit as the first apoptosis-targeted drugs enter early clinical trials. This chapter provides a selective review on the development of such drugs. We also outline issues regarding the regulation and design of early clinical trials of this type of molecularly targeted agent. Finally, we discuss the biomarkers and surrogate pharmacodynamic endpoint assays currently available to chart the efficacy of apoptosis-inducing anticancer therapy.


Files in this item

This item appears in the following Collection(s)

Show simple item record